China Develops 2 Effective Drugs to Relieve Moderate Symptoms of Covid


Jakarta, CNN Indonesia —

State-owned pharmaceutical company China, Sinopharm, is developing two drug corona virus SARS-CoV-2.

The vice president and chief scientist of China National Biotech Group (CNBG), Zhang Yuntao, claimed that the two drugs were effective in curing COVID-19 sufferers with mild to moderate symptoms.

CNBG is a subsidiary of Sinopharm which is currently researching the two Covid-19 drugs.

“The two drugs were developed based on human immunoglobulins and monoclonal antibodies which are used to neutralize the virus and reduce the amount of virus that enters the human body,” Zhang said.

Zhang said one of the two Covid-19 drugs had been exhibited during the 2021 China international trade fair in early September.

CNBG claims this Covid-19 drug is the first in the world to be made with human immunoglobulins developed from the blood plasma of Covid-19 survivors.

The drug is also said to contain high levels of coronavirus neutralizing antibodies against SARS-CoV-2.

Zhang said the drug will undergo clinical trials and that it is working with international partners to develop the discovery.

Meanwhile, another Covid-19 drug consists of a monoclonal antibody, which can effectively stop the novel coronavirus from increasing its resistance to the angiotensin-converting enzyme 2.

The enzyme is attached to cell membranes located in the intestines, kidneys, testes, gallbladder, and heart.

Monoclonal antibodies can prevent viruses from infecting cells in the human body.

The Sinopharm research team said this drug is claimed to be able to relieve symptoms of the Delta variant of the corona virus which is considered more virulent and fast-paced and is spreading in most countries in the world.

See also  Video: Google publishes data on behavior in corona crisis

To a Chinese newspaper, Global Times, Chinese officials said that this research puts Bamboo Curtain Country among other leading countries in developing Covid-19 treatments.

CNBG’s senior clinical trial leader, Zhu Jingjin, said the development of a Covid-19 treatment method with convalescent plasma had also been included in the national coronavirus patient treatment plan.

CNBG also said that it had carried out a strict selection process for blood plasma donors which became the main material for Covid-19 treatment.

(rds/rds)

[Gambas:Video CNN]


.

Leave a Comment